Clinical Trial Update: Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the DOS regimen (Docetaxel, Oxaliplatin, S-1) as neoadjuvant chemotherapy for advanced gastric cancer; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• DOS regimen (Docetaxel+Oxaliplatin+S-1)

Snippet

Sponsor: Sanofi | Conditions: Gastric Cancer | Phase 3 | Status: COMPLETED | Results posted: 2020-03-02